GT-EPIC™ Platform Based Personalized Cancer Vaccines to Treat Patients with Advanced Hepatocellular Carcinoma in Combination with PD1 Checkpoint Immunotherapy
Time: 2:30 pm
day: Day One
Details:
- Sharing clinical data highlighting objective responses evaluated via RECIST 1.1
- Understanding what can biomarkers inform us for predicting cancer vaccine driven clinical and immunological responses in checkpoint combinations
